---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-23-000054"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:11:05.752543+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad completes $650M share repurchase program; plans additional authorization in Q3

## Summary
- Q2-to-date repurchased $207.4M of Class A common stock, 549,863 shares at avg $377.20.
- Aggregate repurchases reach the $650M limit authorized by Board in Nov 2017, July 2020, and July 2022.
- Management intends to seek Board approval for additional repurchase authority in Q3 2023.

## SEC filing metadata
- accession: 0000012208-23-000054
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220823000054/0000012208-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220823000054/bio-20230605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-23-000054
- JSON: https://secwatch.observer/filing/0000012208-23-000054.json
- Plain text: https://secwatch.observer/filing/0000012208-23-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.